Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRND | Q07001 | 8/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.46 |
| ▸ | CHRNG | P07510 | 4/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CD40 | P25942 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26572207 | 1.00 | CHRND (0.46) | CHRNDCHRNA1CHRNGCHRNB1MMP2 | |
| SCHEMBL25758188 | 0.90 | CHRNB2 (0.43) | CHRNDCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL25757406 | 0.90 | CHRNB2 (0.43) | CHRNDCHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL25878875 | 0.88 | OPRD1 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4OPRD1 | |
| SCHEMBL25877071 | 0.88 | AKT1 (0.44) | OPRD1OPRM1OPRK1 | |
| SCHEMBL25877236 | 0.88 | AKT1 (0.44) | OPRD1OPRM1OPRK1 | |
| SCHEMBL25877257 | 0.88 | AKT1 (0.44) | OPRD1OPRM1OPRK1 | |
| SCHEMBL25877675 | 0.87 | OPRD1 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4OPRD1 | |
| SCHEMBL26572532 | 0.84 | CHRND (0.47) | CHRNDCHRNA1CHRNGCHRNB1MMP2 | |
| SCHEMBL25874361 | 0.83 | MMP2 (0.56) | CHRNDCHRNA1CHRNGCHRNB1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | CHRND 4142/4885CHRNA1 4443/4885CHRNG 4842/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | CHRND 4142/4885CHRNA1 4443/4885CHRNG 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.